Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
Standard BioTools (NASDAQ:LAB) announced that PRECISE-SG100K has selected their SomaScan 11K Assay to analyze 100,000 plasma samples from their biobank after evaluating competitive proteomics platforms.
The collaboration represents one of the world's largest population health research studies, leveraging Singapore's multi-ethnic population. Standard BioTools' SomaScan platform was chosen for its superior proteome coverage, reproducibility, and service quality. The company has established itself as a leader in population proteomics, with SomaScan being used in over 30 biobank studies globally, including three major additions this year totaling nearly 160,000 samples.
Standard BioTools (NASDAQ:LAB) ha annunciato che PRECISE-SG100K ha scelto il loro SomaScan 11K Assay per analizzare 100.000 campioni di plasma provenienti dalla loro biobanca, dopo aver valutato diverse piattaforme proteomiche concorrenti.
Questa collaborazione rappresenta uno degli studi di ricerca sulla salute della popolazione più grandi al mondo, sfruttando la popolazione multietnica di Singapore. La piattaforma SomaScan di Standard BioTools è stata selezionata per la sua eccellente copertura del proteoma, riproducibilità e qualità del servizio. L'azienda si è affermata come leader nella proteomica di popolazione, con SomaScan utilizzato in oltre 30 studi su biobanche a livello globale, inclusi tre importanti nuovi progetti quest'anno che complessivamente raggiungono quasi 160.000 campioni.
Standard BioTools (NASDAQ:LAB) anunció que PRECISE-SG100K ha seleccionado su SomaScan 11K Assay para analizar 100,000 muestras de plasma de su biobanco, tras evaluar plataformas proteómicas competitivas.
La colaboración representa uno de los estudios de investigación en salud poblacional más grandes del mundo, aprovechando la población multiétnica de Singapur. La plataforma SomaScan de Standard BioTools fue elegida por su superior cobertura del proteoma, reproducibilidad y calidad de servicio. La compañía se ha consolidado como líder en proteómica poblacional, con SomaScan utilizado en más de 30 estudios de biobancos a nivel global, incluyendo tres importantes incorporaciones este año que suman casi 160,000 muestras.
Standard BioTools (NASDAQ:LAB)는 경쟁력 있는 단백질체 플랫폼 평가 후, PRECISE-SG100K가 그들의 SomaScan 11K Assay를 선택해 바이오뱅크에서 100,000개의 혈장 샘플을 분석한다고 발표했습니다.
이번 협력은 싱가포르의 다민족 인구를 활용한 세계 최대 규모의 인구 건강 연구 중 하나입니다. Standard BioTools의 SomaScan 플랫폼은 뛰어난 단백질체 범위, 재현성, 서비스 품질로 선택되었습니다. 이 회사는 인구 단백질체학 분야에서 선도적인 위치를 확립했으며, SomaScan은 전 세계 30개 이상의 바이오뱅크 연구에 사용되고 있습니다. 올해에는 세 건의 주요 프로젝트가 추가되어 총 거의 160,000개의 샘플에 달합니다.
Standard BioTools (NASDAQ:LAB) a annoncé que PRECISE-SG100K a choisi leur SomaScan 11K Assay pour analyser 100 000 échantillons de plasma issus de leur biobanque, après avoir évalué des plateformes protéomiques concurrentes.
Cette collaboration représente l'une des plus grandes études de recherche en santé de population au monde, tirant parti de la population multiethnique de Singapour. La plateforme SomaScan de Standard BioTools a été retenue pour sa couverture protéomique supérieure, sa reproductibilité et la qualité de son service. L'entreprise s'est imposée comme un leader en protéomique de population, avec SomaScan utilisé dans plus de 30 études de biobanques à l'échelle mondiale, incluant trois ajouts majeurs cette année totalisant près de 160 000 échantillons.
Standard BioTools (NASDAQ:LAB) gab bekannt, dass PRECISE-SG100K ihr SomaScan 11K Assay ausgewählt hat, um 100.000 Plasmaproben aus ihrer Biobank zu analysieren, nachdem verschiedene proteomische Plattformen bewertet wurden.
Die Zusammenarbeit stellt eine der weltweit größten bevölkerungsbezogenen Gesundheitsstudien dar und nutzt die multiethnische Bevölkerung Singapurs. Die SomaScan-Plattform von Standard BioTools wurde aufgrund ihrer überlegenen Proteomabdeckung, Reproduzierbarkeit und Servicequalität gewählt. Das Unternehmen hat sich als führend in der Bevölkerungsproteomik etabliert, wobei SomaScan in über 30 Biobank-Studien weltweit eingesetzt wird, darunter drei bedeutende Neuzugänge in diesem Jahr mit insgesamt fast 160.000 Proben.
- Selected as exclusive provider for one of world's largest population health research studies
- Platform chosen over competitors for superior proteome coverage and reproducibility
- Expanding presence in biobank segment with over 30 studies worldwide
- Recent expansion with three major biobank additions totaling 160,000 samples in 2025
- None.
Insights
Standard BioTools secures major contract for 100,000-sample proteomics analysis in Singapore's landmark population health study, strengthening market position.
Standard BioTools has secured a significant commercial win with its SomaScan 11K Assay being selected by Singapore's PRECISE-SG100K to analyze 100,000 plasma samples from their biobank. This selection came after a competitive evaluation process where SomaScan's superior proteome coverage and reproducibility outperformed competing technologies.
This deal represents more than just a one-off contract; it strategically positions Standard BioTools as a dominant player in the high-value biobank proteomics segment. The company has now secured contracts for nearly 160,000 samples this year alone across multiple major biobanks, including the HUNT Biobank in Norway (17,000 samples) and the UK Biobank (50,000 samples).
The selection for the PRECISE-SG100K project is particularly valuable because population health studies generate comprehensive datasets that reveal gene-to-protein correlations and potential therapeutic targets. These studies require exceptional data quality and reproducibility across large sample sets – precisely where SomaScan technology excels.
For context, proteomics technologies that can reliably analyze tens of thousands of samples represent a significant advancement over traditional methods that were limited in scale and reproducibility. Standard BioTools' platform appears to be winning the commercial battle for large-scale proteomics contracts, which should translate to consistent revenue streams and potential technology licensing opportunities.
This partnership also validates Standard BioTools' technical approach in the competitive proteomics landscape, where several companies are vying for market dominance with different technological approaches to protein measurement. The PRECISE-SG100K study's multi-ethnic focus further demonstrates the platform's versatility across diverse populations.
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine
Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K biobank following a comprehensive evaluation of competitive proteomics offerings.
The combination of unmatched proteome coverage, superior reproducibility and high-quality service offering positioned SomaScan as the platform of choice, delivering the greatest overall value to this landmark initiative.
“Our vision is to shape the future of precision medicine through one of the world’s most ambitious population health research programs,” said Professor John Chambers, Chief Scientific Officer of PRECISE and Lead Investigator of SG100K population cohort study. “Realizing the full potential of a biobank initiative like PRECISE-SG100K requires moving beyond measuring a limited set of proteins in new samples to truly enable the discovery of novel genetic associations and biomarkers. This collaboration delivers on that promise and sets a new benchmark for population-scale proteomics.”
PRECISE-SG100K aims to transform healthcare in Singapore and improve patient outcomes through data-driven solutions. The project is one of the world’s largest and most impactful population health research studies, drawing on Singapore’s multi-ethnic population with supporting data from participant questionnaires and extensive participant health insights.
“Biobank investigators are advancing our knowledge about the biology of diverse populations around the world using proteomics. Platform choice is mission critical for these researchers and needs to be focused on throughput, reproducibility and depth of measurement,” said Stephen Williams, MD, PhD, Chief Medical Officer of Standard BioTools. “The SomaScan Platform was designed to provide the highest coverage, with the best precision, making it ideally suited for biobanks and population health studies.”
Standard BioTools is a leader in population proteomics with SomaScan having been used in more than 30 biobank studies worldwide, including three major additions this year totaling nearly 160,000 samples. In June, BioAge Labs announced it will use the SomaScan technology to profile more than 17,000 samples from the HUNT Biobank in Norway to further understand the biology of human aging with the goal of developing therapeutics for metabolic diseases.
In January, Illumina and biopharma collaborators launched a pilot proteomics program to analyze 50,000 UK Biobanks samples leveraging the new Illumina Protein Prep NGS-based proteomics platform, powered by Standard BioTools’ SOMAmer™ technology, to provide deeper biological insights.
Population proteomics studies are generating new datasets that enable a more comprehensive overview of the dynamics of protein expression in a wide range of biological samples such as plasma, serum, urine and CSF, revealing new insights into gene-to-protein correlations, novel biology, mechanisms of action and new therapeutic targets. You can read more about Standard Biotools’ work with biobanks around the world here: https://somalogic.com/somascan-assay-biobanks
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook and LinkedIn.
About Precision Health Research, Singapore (PRECISE)
PRECISE coordinates Singapore's National Precision Medicine Phase II programme, a multi-institutional collaboration including A*STAR, Lee Kong Chian School of Medicine, National Healthcare Group, National University Health System, National University of Singapore, and SingHealth Duke-NUS Academic Medical Centre. The programme studies the genetic makeup of 100,000 Singaporeans to improve healthcare outcomes through Asian genome insights. Working with A*STAR, the Biomedical Sciences Industry Partnership Office, and EDB, the programme also aims to grow Singapore's precision medicine industry by attracting international companies and creating opportunities for local enterprises. The initiative is supported by the National Research Foundation, Singapore under the RIE2020 White Space (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health through the National Medical Research Council Office, MOH Holdings Pte Ltd.
For more information, pls visit https://www.npm.sg
About SG100K
The SG100K study is a long-term project focusing on the health and well-being of Singapore's diverse, multi-ethnic population. The study aims to engage over 100,000 participants and collect baseline health information and biological specimens. The study will monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension, and cancer. The SG100K study will be a significant resource for promoting health in Singapore and will yield globally significant results.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Media Contact
Emilia Costales
emilia.costales@standardbio.com
Investor Contact
ir@standardbio.com
FAQ
What is the significance of Standard BioTools' collaboration with PRECISE-SG100K?
How many biobank studies has Standard BioTools' SomaScan platform been used in?
What are the key advantages of Standard BioTools' SomaScan platform?
What recent major biobank collaborations has Standard BioTools (LAB) secured in 2025?
What is the purpose of PRECISE-SG100K's population health study?
